KPTI vs MS · rev $68.5M vs P/E 20, rev $41.93B
Karyopharm Therapeutics Inc (KPTI) versus Morgan Stanley (MS) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported MS revenue for 2026-06-30 was $41.93B. Net income was $11.15B. MS currently screens at market cap $344.27B and trailing P/E 19.8.
KPTI currently screens at market cap $205.6M. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Not investment advice. Open the KPTI and MS stock pages for the full models.
Not investment advice.